




PCT/EP03 / 03341

10/50341



INVESTOR IN PEOPLE



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Signed *Answer*

Dated 30 April 2003



Patents Act 1977
(Rule 16)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

AWGP/JW/PG 00473587003
E709706-1 C69803
P01/7700 0.00-0208158.6

2. Patent application number

(The Patent Office will fill in his part) 28 MAR 2002

0208158.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number (if you know it) 004-73587003

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Novel Compounds

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

GlaxoSmithKline
Corporate Intellectual Property CN925.1
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (if you know it) 07960982003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

9. Enter the number of sheets for any following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	32
Description	6
Claim(s)	1
Abstract	
Drawings	

5

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. We request the grant of a patent on the basis of this application
Signature H B Dawson Date 28-Mar-02

12. Name and daytime telephone number of person to contact in the United Kingdom
H B Dawson 01279 644689

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- f) For details of the fee and ways to pay please contact the Patent Office.

Novel Compounds

This invention relates to novel compounds, processes for their preparation, pharmaceutical formulations containing them and their use in
5 therapy.

Inflammation is a primary response to tissue injury or microbial invasion and is characterised by leukocyte adhesion to the endothelium, diapedesis and activation within the tissue. Leukocyte activation can result in the generation of toxic oxygen species (such as superoxide anion), and the release of granule
10 products (such as peroxidases and proteases). Circulating leukocytes include neutrophils, eosinophils, basophils, monocytes and lymphocytes. Different forms of inflammation involve different types of infiltrating leukocytes, the particular profile being regulated by the profile of adhesion molecule, cytokine and chemotactic factor expression within the tissue.

15 The primary function of leukocytes is to defend the host from invading organisms, such as bacteria and parasites. Once a tissue is injured or infected, a series of events occurs which causes the local recruitment of leukocytes from the circulation into the affected tissue. Leukocyte recruitment is controlled to allow for the orderly destruction and phagocytosis of foreign or dead cells,
20 followed by tissue repair and resolution of the inflammatory infiltrate. However in chronic inflammatory states, recruitment is often inappropriate, resolution is not adequately controlled and the inflammatory reaction causes tissue destruction.

There is increasing evidence that the bronchial inflammation which is characteristic of asthma represents a specialised form of cell-mediated immunity,
25 in which cytokine products, such as IL-4 and IL-5 released by T-helper 2 (Th2) lymphocytes, orchestrate the accumulation and activation of granulocytes, in particular eosinophils and to a lesser extent basophils. Through the release of cytotoxic basic proteins, pro-inflammatory mediators and oxygen radicals, eosinophils generate mucosal damage and initiate mechanisms that underlie
30 bronchial hyperreactivity. Therefore, blocking the recruitment and activation of Th2 cells and eosinophils is likely to have anti-inflammatory properties in asthma. In addition, eosinophils have been implicated in other disease types such as rhinitis, eczema, irritable bowel syndrome and parasitic infections.

Chemokines are a large family of small proteins which are involved in
35 trafficking and recruitment of leukocytes (for review see Luster, New Eng. J. Med., 338, 436-445 (1998)). They are released by a wide variety of cells and act to attract and activate various cell types, including eosinophils, basophils, neutrophils, macrophages, T and B lymphocytes. There are two major families of chemokines, CXC- (α) and CC- (β) chemokines, classified according to the
40 spacing of two conserved cysteine residues near to the amino terminus of the

chemokine proteins. Chemokines bind to specific cell surface receptors belonging to the family of G-protein-coupled seven transmembrane-domain proteins (for review see Luster, 1998). Activation of chemokine receptors results in, amongst other responses, an increase in intracellular calcium, changes in cell shape, increased expression of cellular adhesion molecules, degranulation and promotion of cell migration (chemotaxis).

To date a number of CC chemokine receptors have been identified and of particular importance to the current invention is the CC-chemokine receptor-3 (CCR-3), which is predominantly expressed on eosinophils, and also on basophils, mast cells and Th2 cells. Chemokines that act at CCR-3, such as RANTES, MCP-3 and MCP-4, are known to recruit and activate eosinophils. Of particular interest are eotaxin and eotaxin-2, which specifically bind to CCR-3. The localization and function of CCR-3 chemokines indicate that they play a central role in the development of allergic diseases such as asthma. Thus, CCR-3 is specifically expressed on all the major cell types involved in inflammatory allergic responses. Chemokines that act at CCR-3 are generated in response to inflammatory stimuli and act to recruit these cell types to sites of inflammation, where they cause their activation (e.g. Griffiths et al., J. Exp. Med., 179, 881-887 (1994), Lloyd et al., J. Exp. Med., 191, 265-273 (2000)). In addition, anti-CCR-3 monoclonal antibodies completely inhibit eotaxin interaction with eosinophils (Heath, H. et al., J. Clin. Invest. 99 (2), 178-184 (1997)), while an antibody for the CCR-3 specific chemokine, eotaxin, reduced both bronchial hyperreactivity and lung eosinophilia in an animal model of asthma (Gonzalo et al., J. Exp. Med., 188, 157-167 (1998). Thus, many lines of evidence indicate that antagonists at the CCR-3 receptor are very likely to be of therapeutic use for the treatment of a range of inflammatory conditions.

In addition to a key role in inflammatory disorders, chemokines and their receptors also play a role in infectious disease. Mammalian cytomegaloviruses, herpes viruses and pox viruses express chemokine receptor homologues, which can be activated by human CC chemokines such as RANTES and MCP-3 receptors (for review see Wells and Schwartz, Curr. Opin. Biotech., 8, 741-748, 1997). In addition, human chemokine receptors, such as CXCR-4, CCR-5 and CCR-3, can act as co-receptors for the infection of mammalian cells by microbes such as human immunodeficiency viruses (HIV). Thus, chemokine receptor antagonists, including CCR-3 antagonists, may be useful in blocking infection of CCR-3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses.

International Patent Application publication number WO 01/24786 (Shionogi & Co. Ltd.) discloses certain aryl and heteroaryl derivatives for treating diabetes. WO 00/69830 (Torrey Pines Institute for Molecular Studies) discloses


- certain diazacyclic compounds, and libraries containing them, for biological screening. WO 00/18767 (Neurogen Corporation) discloses certain piperazine derivatives as dopamine D4 receptor antagonists. United States Patent 6,031,097 and WO 99/21848 (Neurogen Corporation) discloses certain
- 5 aminoisoquinoline derivatives as dopamine receptor ligands. WO 99/06384 (Recordati Industria Chimica) discloses piperazine derivatives useful for the treatment of neuromuscular dysfunction of the lower urinary tract. WO 98/56771 (Schering Aktiengesellschaft) discloses certain piperazine derivatives as anti-inflammatory agents. WO 97/47601 (Yoshitomi Pharmaceutical Industries Ltd.)
- 10 discloses certain fused heterocyclic compounds as dopamine D-receptor blocking agents. WO 96/39386 (Schering Corporation) discloses certain piperidine derivatives as neurokinin antagonists. WO 96/02534 (Byk Gulden Lomberg Chemische Fabrik GmbH) discloses certain piperazine thiopyridines useful for controlling helicobacter bacteria. WO 95/32196 (Merck Sharp &
- 15 Dohme Limited) discloses certain piperazine, piperidine, and tetrahydropyridine derivatives as 5-HT1D-alpha antagonists. United States Patent 5,389,635 (E.I. Du Pont de Nemours and Company) discloses certain substituted imadazoles as angiotensin-II antagonists. European Patent Application publication number 0 306 440 (Schering Aktiengesellschaft) discloses certain imidazole derivatives as
- 20 cardiovascular agents.

A novel group of compounds has now been found which are CCR-3 antagonists. These compounds block the migration/chemotaxis of eosinophils and thus possess anti-inflammatory properties. These compounds are therefore of potential therapeutic benefit, especially in providing protection from eosinophil,

25 basophil mast cell and Th2-cell-induced tissue damage in diseases where such cell types are implicated, particularly allergic diseases, including but not limited to bronchial asthma, allergic rhinitis and atopic dermatitis.

Thus, according to one aspect of the invention, there are provided compounds of formula (I):

30



wherein:

R¹ represents substituted or unsubstituted heteroaryl;

Y represents $-(CR_{na}R_{nb})_n-$;

R_{na} and R_{nb} are each independently hydrogen or C_{1-6} alkyl;

n is an integer from 1 to 5;

R^2 represents unsubstituted or substituted aryl or unsubstituted or

5 substituted heteroaryl;

R^3 represents hydrogen or C_{1-6} alkyl;

and salts and solvates thereof;

with the provisos that;

R^1 is not oxazolyl;

10 R^1 is not substituted by phenyl, and;

the following compounds are excluded;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-thien-3-ylacetamide;

15 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)acetamide;

2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide;

20 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-furyl)acetamide;

2-(3-acetyl-1-benzothien-4-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide trifluoroacetate;

2-(5-bromopyridin-3-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-

25 -yl]methyl]acetamide compound with formic acid (1:1);

N-[[4-((2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(2-furyl)acetamide;

2-(4-bromo-1H-imidazol-1-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide;

30 N-[[4-(3,4-difluorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

N-[[4-(4-fluorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

N-[[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

35 N-[[4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

N-[[4-(3-chlorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

40 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methyl-2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;

- methyl 2-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-2H-1,2,3-benzotriazole-5-carboxylate;
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(1H-pyrrolo[2,3-b]pyridin-1-yl)acetamide;
 5 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-pyridin-2-yl-2H-tetraazol-2-yl)acetamide;
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-pyridin-3-yl-2H-tetraazol-2-yl)acetamide;
 methyl 1-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-1H-1,2,3-benzotriazole-5-carboxylate compound with methyl 1-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-1H-1,2,3-benzotriazole-6-carboxylate (1:1);
 N-((2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-methyl-2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide, and;
 15 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(2,3-dimethylquinoxalin-6-yl)acetamide.

Examples of the heteroaryl group, R¹, include furanyl, isoxazolyl, tetrazolyl and pyrazolyl.

- When R¹ is substituted heteroaryl, suitable substituents include C₁₋₆alkylsulphonylamino; C₁₋₆alkylcarbonyl; aminocarbonyl; unsubstituted heterocyclyl; heterocyclyl substituted with C₁₋₆alkyl, halo, C₁₋₆alkoxy, or hydroxy; unsubstituted heteroaryl; heteroaryl substituted with C₁₋₆alkyl, halo, C₁₋₆alkoxy, or hydroxy; perhaloC₁₋₆alkyl; C₁₋₆alkyl; C₁₋₆alkoxycarbonyl; mono- and di-(C₁₋₆alkyl)aminocarbonyl; halo; C₁₋₆alkoxy; nitro; C₁₋₆alkylsulphonyl; hydroxy; C₁₋₆alkoxyC₁₋₆alkyl; C₁₋₆alkylthio; mono- and di-(C₁₋₆alkyl)amino;
 25 cycloalkylaminocarbonyl; formyl; and C₁₋₆alkylcarbonylamino.

When R¹ is substituted by unsubstituted or substituted heterocyclyl, examples of said heterocyclyl group include piperidinyl.

- When R¹ is substituted by unsubstituted or substituted heteroaryl, examples of said heteroaryl group include thiazolyl and thiophenyl.

Suitably, R¹ is unsubstituted or substituted isoxazolyl, unsubstituted or substituted pyrazolyl or substituted or unsubstituted tetrazolyl.

When R¹ is substituted pyrazolyl, suitable substituents include C₁₋₆alkyl, perhaloC₁₋₆alkyl, C₁₋₆alkoxycarbonyl, formyl, and unsubstituted heteroaryl.

- When R¹ is substituted tetrazolyl, suitable substituents include unsubstituted heterocyclyl, for example piperidinyl, and C₁₋₆alkyl.

When R¹ is substituted isoxazolyl, suitable substituents include C₁₋₆alkyl.

- More suitably, R¹ is 3-(thiophen-2-yl)-4-(methyl)pyrazol-1-yl, 5-(isopropyl)tetrazol-1-yl, 5-methyl-3-(trifluoromethyl)pyrazol-1-yl, 3-(thiazol-2-yl)pyrazol-1-yl, 5-(piperidin-1-yl)tetrazol-2-yl, 5-(piperidin-1-yl)tetrazol-1-yl, 1-

(methyl)tetrazol-5-yl, tetrazol-5-yl, 5-(methyl)isoxazol-3-yl, 5-(*iso*-propyl)tetrazol-2-yl, 2-(methyl)tetrazol-5-yl, 3-(methyl)isoxazol-5-yl, 3-(formyl)pyrazol-1-yl, 3-(methyl)pyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, or 4-(ethoxycarbonyl)pyrazol-1-yl.

Suitably, R_{na} and R_{nb} are both hydrogen.

5 Suitably, n is 1.

Suitably, R^3 is hydrogen.

When R^2 is aryl, examples include phenyl.

When R^2 is substituted aryl, suitable substituents include cyano, perhalo C_{1-6} alkyl, amido, halo, C_{1-6} alkyl, C_{1-6} alkoxycarbonyl, mono- and di-(C_{1-6} alkyl)aminocarbonyl, C_{1-6} alkoxy, nitro, C_{1-6} alkylsulphonyl, hydroxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkylthio, mono- and di-(C_{1-6} alkyl)amino, and C_{1-6} alkylcarbonylamino.

When R^2 is heteroaryl, examples include thiophenyl.

When R^2 is substituted heteroaryl, suitable substituents include cyano, perhalo C_{1-6} alkyl, amido, halo, C_{1-6} alkyl, C_{1-6} alkoxycarbonyl, mono- and di-(C_{1-6} alkyl)aminocarbonyl, C_{1-6} alkoxy, nitro, C_{1-6} alkylsulphonyl, hydroxy, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkylthio, mono- and di-(C_{1-6} alkyl)amino, and C_{1-6} alkylcarbonylamino.


Suitably, R^2 is unsubstituted or substituted phenyl or unsubstituted or substituted thiophenyl.

When R^2 is substituted phenyl suitable substituents include halo.

20 More suitably, R^2 is phenyl substituted with chloro or fluoro.

Preferably, R^2 is 3,4-difluorophenyl or 3,4-dichlorophenyl.

There exists a preferred subgroup of compounds of formula (I) being of formula (I')



25

wherein;

R^1 is unsubstituted or substituted heteroaryl, and;

R^2 is phenyl substituted with halo.

30 Suitably, R^1 is pyrazolyl substituted with thiophenyl, thiazolyl, formyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkyl, or perhalo C_{1-6} alkyl; unsubstituted tetrazolyl or tetrazolyl substituted with piperidinyl or C_{1-6} alkyl; or isoxazolyl substituted with C_{1-6} alkyl.

Preferably, R¹ is 3-(thiazol-2-yl)pyrazol-1-yl, 5-(1-piperidinyl)tetrazol-2-yl, 5-(*iso*-propyl)tetrazol-2-yl, 2-methyltetrazol-5-yl, 4-methyl-3-(thiophen-2-yl)pyrazol-1-yl, 5-(*iso*-propyl)tetrazol-1-yl, 5-methyl-3-(trifluoromethyl)pyrazol-1-yl, 5-(piperidin-1-yl)tetrazol-1-yl, 1-methyltetrazol-5-yl, tetrazol-5-yl, 3-
 5 (methyl)isoxazol-5-yl, 3-(formyl)pyrazol-1-yl, 3-(methyl)pyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 4-(ethoxycarbonyl)pyrazol-1-yl, or 5-methylisoxazol-3-yl.

Suitably, R² is phenyl substituted with chloro or fluoro.

Preferably, R² is 3,4-dichlorophenyl or 3,4-difluorophenyl.

Suitably, the stereochemistry at the position marked '*' is (S).

10 Accordingly, there is provided a compound of formula (I') or a salt or solvate thereof.

Suitable salts of the compounds of formula (I) include physiologically acceptable salts and salts which may not be physiologically acceptable but may be useful in the preparation of compounds of formula (I) and physiologically
 15 acceptable salts thereof. If appropriate, acid addition salts may be derived from inorganic or organic acids, for example hydrochlorides, hydrobromides, sulphates, phosphates, acetates, benzoates, citrates, succinates, lactates, tartrates, fumarates, maleates, 1-hydroxy-2-naphthoates, palmoates, methanesulphonates, formates or trifluoroacetates.

20 Examples of solvates include hydrates.

Certain of the compounds of formula (I) may contain chiral atoms and/or multiple bonds, and hence may exist in one or more stereoisomeric forms. The present invention encompasses all of the stereoisomers of the compounds of formula (I), including geometric isomers and optical isomers, whether as
 25 individual stereoisomers or as mixtures thereof including racemic modifications.

Generally it is preferred that a compound of formula (I) is in the form of a single enantiomer or diastereoisomer.

Certain of the compounds of formula (I) may exist in one of several tautomeric forms. It will be understood that the present invention encompasses
 30 all of the tautomers of the compounds of formula (I) whether as individual tautomers or as mixtures thereof.

References to 'aryl' refer to monocyclic and bicyclic carbocyclic aromatic rings, for example naphthyl and phenyl, especially phenyl.

Suitable substituents for any aryl group include 1 to 5, suitably 1 to 3,
 35 substituents selected from the list consisting of cyano, perhaloalkyl, amido, halo, alkyl, alkoxycarbonyl, mono- and di-(alkyl)aminocarbonyl, alkoxy, nitro, alkylsulphonyl, hydroxy, alkoxyalkyl, alkylthio, mono- and di-(alkyl)amino, and alkylcarbonylamino.

References to 'heteroaryl' refer to monocyclic heterocyclic aromatic rings
 40 containing 1-4 heteroatoms selected from nitrogen, oxygen and sulphur.

Examples of heterocyclic aromatic rings include thiophenyl, furanyl, thiazolyl, pyrazinyl, tetrazolyl, triazolyl, oxadiazolyl, oxazolyl, isoxazolyl, and pyrazolyl especially pyrazolyl, tetrazolyl, thiazolyl, and isoxazolyl.

- Suitable substituents for any heteroaryl group include 1 to 5, suitably 1 to 3, substituents selected from the list consisting of alkylsulphonylamino; alkylcarbonyl; aminocarbonyl; unsubstituted heterocyclyl; heterocyclyl substituted with alkyl, halo, alkoxy, or hydroxy; unsubstituted heteroaryl; heteroaryl substituted with alkyl, halo, alkoxy, or hydroxy; perhaloalkyl; alkyl; alkoxycarbonyl; mono- and di-(alkyl)aminocarbonyl; halo; alkoxy; nitro; alkylsulphonyl; hydroxy; alkoxyalkyl; alkylthio; mono- and di-(alkyl)amino; cycloalkylaminocarbonyl; cyano; alkylcarbonylamino; and amido.

References to 'alkyl' refer to both straight chain and branched chain aliphatic isomers of the corresponding alkyl, suitably containing up to six carbon atoms.

- References to 'cycloalkyl' refer to saturated alicyclic rings suitably containing 3-8 carbon atoms.

Suitable substituents for any cycloalkyl group include alkyl, halo, and hydroxy.



- References to 'heterocyclyl' refer to monocyclic heterocyclic aliphatic rings containing 2 to 6, suitably 3 to 5, carbon atoms, and 1 to 3, heteroatoms selected from nitrogen, oxygen, and sulphur. Examples of heterocyclic rings include piperidinyl.

Suitable substituents for any heterocyclyl group include alkyl, halo, alkoxy, or hydroxy.

- References to 'halogen' or 'halo' refer to iodo, bromo, chloro or fluoro, especially fluoro and chloro.

The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention.

- Accordingly, there is provided a process for the preparation of a compound of formula (I) which process comprises the reaction of a compound of formula (II) with a compound of formula (III);



35

wherein:

R^1 , Y , R^3 , and R^2 are as hereinbefore defined for formula (I) in the presence of an activating agent and a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- 5 (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

Suitably, the activating agent is 1-hydroxybenzotriazole (HOBT).

- Examples of peptide coupling agents are 1,3-dicyclohexylcarbodiimide (DCC); 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) and 1-(3-
- 10 dimethylaminopropyl)-3-ethylcarbodiimide, or a salt thereof. Suitably, the peptide coupling agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.


- Typically, the compound of formula (II) and the compound of formula (III) in a suitable solvent, such as a polar organic solvent, e.g. N,N-dimethylformamide are treated with a peptide coupling agent at ambient
- 15 temperature, such as about 18 - 25°C. The reaction mixture is stirred at ambient temperature for an appropriate time period, such as about 12 - 20 hours.

A compound of formula (III) wherein R^3 is hydrogen may be prepared either by Reaction (a) or Reaction (c). The S-enantiomer of a compound of formula (III) may be prepared by Reaction (b).

- 20 Reaction (a). Reaction of the compound of formula (IV) with a compound of formula (V)



- 25 wherein R^2 is as hereinbefore defined for formula (I) and A is a protected amino group, suitably phthalimido, followed by deprotection of the amino group to give a compound of formula (III) wherein R^3 is hydrogen i.e. a compound of formula (IIIR)



wherein R^2 is as hereinbefore defined, and optionally resolution of the resulting enantiomers of a compound of formula (IIIR);


or;

Reaction (b). Reaction of a compound of formula (IV) as hereinbefore defined with a compound of formula (VA)



5


wherein A is as hereinbefore defined for formula (V), followed by deprotection of the amino group to give the corresponding enantiomer of a compound of formula (III) wherein R^3 is hydrogen i.e. a compound of formula (IIIE)



10

wherein R^2 is as hereinbefore defined.

Reaction (c). Hydrolysis of a compound of formula (VI);



15

wherein T is trifluoroacetyl, and R^3 and R^2 are as hereinbefore defined for formula (I), and optionally resolution of the resulting enantiomers of a compound of formula (III).



20 For both reactions (a) and (b), the cyclisation of the intermediate diols (IIIBR) and (IIIBE) in the reaction between the compound of formula (IV) and a compound of formula (V) or (VA) is typically carried out under the Mitsunobu conditions as follows:

25 Typically, a mixture of the compound of formula (IV) and the compound of formula (V) or formula (VA) in a suitable solvent, such as tetrahydrofuran, is stirred, suitably for 20-24 hours at a suitable temperature, suitably the reflux temperature of the solvent, under an inert atmosphere, suitably an atmosphere of nitrogen. Further solvent is then added and the mixture cooled, suitably to 0-5°C. A suitable phosphine, suitably triphenyl phosphine, is added and the

mixture stirred until all the solid is dissolved. A suitable azo compound, suitably diisopropylazodicarboxylate, is then added over a period of time, suitably, 10-15 minutes, while maintaining the temperature at $<7^{\circ}\text{C}$. The mixture is allowed to stand for a period of time, suitably 2-3 hours, then allowed to warm, suitably to 20-25 $^{\circ}\text{C}$. After a further period of standing, suitably 4-6 hours, further phosphine and azo compound are added. After a further period of standing, suitably 20-24 hours, the reaction mixture is concentrated to near dryness. A suitable alcohol, suitably propan-2-ol, is added and the concentration step repeated; the alcohol addition and concentration step is then repeated. Further alcohol is then added and the mixture heated to a temperature suitably between 65-75 $^{\circ}\text{C}$. After a suitable period, suitably 20-45 minutes, the resultant slurry is cooled, suitably to 20-25 $^{\circ}\text{C}$, and then allowed to stand, suitably for 1.5 - 3 hours, after which time the product is isolated by filtration. The filter bed is washed with more alcohol and then dried *in vacuo* at 35-45 $^{\circ}\text{C}$ to yield the protected form of the of formula (IIIR) or formula (IIIE) respectively.

The removal of the protecting group from the product is typically carried out as follows. A slurry of the protected form of the of formula (IIIR) or formula (IIIE) in an appropriate polar solvent, suitably water, is heated to elevated temperature, suitably 70-75 $^{\circ}\text{C}$ and then treated dropwise with a concentrated mineral acid, suitably concentrated sulphuric acid. The mixture was then heated at elevated temperature, suitably the reflux temperature of the solvent, for a suitable period of time, suitably 20-24 hours, after which the reaction mixture was cooled to 20-25 $^{\circ}\text{C}$ and then treated with a suitable apolar solvent, suitably dichloromethane. A base, suitably 0.880 ammonia solution, is then added dropwise, maintaining the temperature between 20-25 $^{\circ}\text{C}$. Further apolar solvent is then added, the aqueous phase then being separated and extracted with further apolar solvent. The combined organic phase is washed with water and then evaporated to dryness. The residue is redissolved and the apolar solvent re-evaporated to give the compound of formula (IIIR) or formula (IIIE).

The process for the preparation of the protected form of the compound of formula (IIIR) or formula (IIIE) described above may also be undertaken in two stages, in which an intermediate compound of formula (IIIBR) or of formula (IIIBE) respectively;



wherein A is as hereinbefore defined for formulae (V) and (VA) and R^2 is as hereinbefore defined for formula (I);
is isolated.



Typically, a mixture of the compound of formula (IV) and a compound of
5 formula (V) or formula (VA) in a suitable solvent, such as tetrahydrofuran, is
stirred, suitably for 20-24 hours at a suitable temperature, suitably the reflux
temperature of the solvent, under an inert atmosphere, suitably an atmosphere of
nitrogen. Further compound of formula (IV) is added and the mixture heated at a
suitable temperature, suitably the reflux temperature of the solvent, under an
10 inert atmosphere, suitably an atmosphere of nitrogen, for a suitable period of
time, suitably 3-6 hours. The reaction mixture is then cooled, suitably to 20-
25°C, and the compound precipitated by means of addition of a suitable co-
solvent, suitably diisopropyl ether. The compound of formula (IIIR) or formula
(IIIE) respectively is isolated by filtration, washed with further co-solvent and
15 dried *in vacuo*.

A protected form of the compound of formula (IIIR) or formula (IIIE) may
then be prepared from a compound of formula (IIIR) or formula (IIIE) under
similar conditions to that of the reaction between a compound of formula (IV) and
formulae (V) or (VA) as hereinbefore described, but omitting the reflux period
20 prior to the addition of the phosphine and azo compounds.

Reaction (c) is typically carried out by stirring a solution of the compound
of formula (VI) in a suitable solvent, for example a mixture of methanol and
water, and adding a suitable base, for example potassium carbonate. The
mixture is stirred at a suitable temperature, for example those in the range 20-
25 25°C for a suitable time, for example 16-20 hours followed by removal of the
organic solvent in vacuo. Water is then added and the mixture extracted with a
suitable organic solvent, for example ethyl acetate. The combined organic
phases are washed with water and saturated aqueous sodium chloride solution
before drying over a suitable drying agent, for example sodium sulphate, filtering
30 and evaporation of the solvent in vacuo. The crude product is then purified by
flash chromatography.

The resolution of the compound of formula (IIIE) from the racemic product
i.e. the compound of formula (IIIR) may be undertaken using techniques well
known to those skilled in the art, for example preparative chiral high performance
35 liquid chromatography (chiral HPLC) or by fractional crystallisation of
diastereoisomeric salts.

A compound of formula (VI) may be prepared by reaction of a compound
of formula (VII) with a compound of formula (VIII)





wherein;

wherein, T , R^3 and R^2 are as hereinbefore defined and L^2 is a leaving group. A suitable leaving group, L^2 is a halo group such as chloro.

The reaction between a compound of formula (VII) and a compound of formula (VIII) is typically carried out by stirring a solution of the compound of formula (VII) in a suitable solvent, for example N,N-dimethylformamide, under an inert atmosphere, for example an atmosphere of nitrogen, with the addition of a suitable base, for example potassium carbonate, and a suitable activating agent such as sodium iodide. A solution of a compound of formula (VIII) in a suitable solvent, such as N,N-dimethylformamide, is added dropwise to the mixture. The mixture is then stirred at a suitable temperature, for example a temperature in the range of 20-25°C, for a suitable period of time, for example 16-20 hours before removing the volatile components in vacuo. The residue is partitioned between a suitable organic solvent, for example dichloromethane, and a saturated aqueous base, for example saturated aqueous sodium carbonate solution. The organic phase is then washed with additional saturated aqueous base and water before drying over a suitable drying agent, for example magnesium sulphate, filtering and evaporation of the solvent in vacuo to yield the crude product. The crude product is purified by flash chromatography.

A compound of formula (VII) may be prepared by reaction of a compound of formula (IX) with a compound of formula (X);




wherein R³ and T are as hereinbefore defined and R_x is an alkyl group, suitably ethyl.

The reaction between a compound of formula (IX) and a compound of formula (X) is typically carried out by stirring a solution of a compound of formula (IX) in a suitable organic solvent, for example methanol, under an inert atmosphere, for example an atmosphere nitrogen, and then adding a solution of a compound of formula (X) in a suitable organic solvent, for example ether. The



mixture is then stirred for a suitable period of time, for example 20-40 minutes at a suitable temperature, for example a temperature in the range of 20-25°C and the volatile components removed in vacuo. The residue is then dissolved in a suitable organic solvent, for example methanol, and the volatile components

5 removed in vacuo.

Additionally, and in a further aspect, a compound of formula (I) wherein Y is -CH₂- and R¹ is an unsubstituted or substituted N-linked heteroaryl group i.e. a compound of formula (XI)



may be prepared by reaction of a compound of formula (XII) with a compound of formula (XIII);



wherein (XII) is an unsubstituted or substituted heteroaryl group, L² is a leaving group, and R³ and R² are as hereinbefore defined for formula (I). Suitable leaving groups are halo groups, preferably bromo.

20 Typically, the reaction between a compound of formula (XII) and a compound of formula (XIII) will be conducted in a suitable organic solvent, such as for example dichloromethane, N,N-dimethylformamide or a mixture thereof, suitably at ambient temperature, e.g. 18 - 25°C for an appropriate time period, e.g. 4 - 10h. A suitable base such as an alkali or alkaline earth metal carbonate, 25 e.g. potassium carbonate, is then added.

A compound of formula (XIII) may be prepared by reaction of a compound of formula (III) with a compound of formula (XIV)



wherein L^2 is as hereinbefore defined for formula (XIII), in the presence of a peptide coupling reagent. Examples of peptide coupling agents are 1,3-dicyclohexylcarbodiimide (DCC); 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, or a salt thereof. Suitably, the peptide coupling agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

Typically, the reaction between a compound of formula (III) and a compound of formula (XIV) is conducted at low temperature, e.g. 0 – 5°C, in a suitable organic solvent such as a haloalkane e.g. dichloromethane, for a suitable time period e.g. 20 – 60 mins.

The compounds of formula (II), certain compounds of formula (III), certain compounds of formula (IV), (V), certain compounds of formula (VI), certain compounds of formula (VII), (VIII), (IX), (X), (XII), and (XIV) are known, commercially available compounds, and/or may be prepared by analogy with known procedures, for examples those disclosed in standard reference texts of synthetic methodology such as *J. March, Advanced Organic Chemistry, 3rd Edition (1985), Wiley Interscience*.

The compounds of formulae (IIIBR), (IIIBE), and (XIII) are considered to be novel.

Accordingly, there is provided a compound of formula (IIIBR).

There is also provided a compound of formula (IIIBE).

There is also provided a compound of formula (XIII).

The above mentioned conversion of a compound of formula (I) into another compound of formula (I) includes any conversion which may be effected using conventional procedures, but in particular the said conversions include converting one group R^1 into another group R^1 .

The above mentioned conversion may be carried out using any appropriate method under conditions determined by the particular groups chosen. Thus, suitable conversions of one group R^1 into another group R^1 include:

(a) converting a group R^1 which represents unsubstituted heteroaryl group into a group R^1 which represents an alkylated heteroaryl group; such a conversion may be carried out using an appropriate conventional alkylating procedure, for example treating an appropriately protected compound of formula (I) with a trialkylsilyldiazomethane.

The above mentioned conversions may as appropriate be carried out on any of the intermediate compounds mentioned herein.

The above mentioned conversions may as appropriate be carried out on any of the intermediate compounds mentioned herein.

Suitable protecting groups in any of the above mentioned reactions are those used conventionally in the art. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected, for example those methods discussed in standard reference texts of synthetic methodology such as *P J Kocienski, Protecting Groups, (1994), Thieme*.

For any of the hereinbefore described reactions or processes, conventional methods of heating and cooling may be employed, for example electric heating mantles and ice/salt baths respectively. Conventional methods of purification, for example crystallisation and column chromatography may be used as required.

Where appropriate individual isomeric forms of the compounds of formula (I) may be prepared as individual isomers using conventional procedures such as the fractional crystallisation of diastereoisomeric derivatives or chiral high performance liquid chromatography (chiral HPLC).

The absolute stereochemistry of compounds may be determined using conventional methods, such as X-ray crystallography.

The salts and solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures.

Compounds of the invention may be tested for *in vitro* biological activity in accordance with the following assay:

25 CCR-3 Binding Assay

A CCR-3 competition binding SPA (scintillation proximity assay) was used to assess the affinity of novel compounds for CCR-3. Membranes prepared from K562 cells stably expressing CCR-3 (2.5µg/well) were mixed with 0.25mg/well wheat-germ agglutinin SPA beads (Amersham) and incubated in binding buffer (HEPES 50 mM, CaCl₂ 1 mM, MgCl₂ 5 mM, 0.5% BSA) at 4°C for 1.5 hr. Following incubation, 20 pM of [¹²⁵I] eotaxin (Amersham) and increasing concentrations of compound (1pM to 30µM) were added and incubated in a 96 well plate for 2 hr at 22°C then counted on a Microbeta plate counter. The total assay volume was 100 µl. Competition binding data were analysed by fitting the data with a four parameter logistic equation. Data are presented as the mean pIC₅₀ values (negative logarithm of the concentration of compound which inhibits [¹²⁵I]eotaxin binding by 50%) from at least two experiments.

The compounds of the Examples were tested in the CCR-3 binding assay. The compounds of the Examples tested in the CCR-3 binding assay possessed pIC₅₀ values in the range 5.5 – 8.5.

Examples of disease states in which the compounds of the invention have potentially beneficial anti-inflammatory effects include diseases of the respiratory tract such as bronchitis (including chronic bronchitis), bronchiectasis, asthma (including allergen-induced asthmatic reactions), chronic obstructive pulmonary disease (COPD), cystic fibrosis, sinusitis and rhinitis.

Also included are diseases of the gastrointestinal tract such as intestinal inflammatory diseases including inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) and intestinal inflammatory diseases secondary to radiation exposure or allergen exposure.

Furthermore, compounds of the invention may be used to treat nephritis; skin diseases such as psoriasis, eczema, allergic dermatitis and hypersensitivity reactions; and diseases of the central nervous system which have an inflammatory component (eg. Alzheimer's disease, meningitis, multiple sclerosis), HIV and AIDS dementia.

Compounds of the present invention may also be of use in the treatment of nasal polyposis, conjunctivitis or pruritis.

Further examples of disease states in which compounds of the invention have potentially beneficial effects include cardiovascular conditions such as atherosclerosis, peripheral vascular disease and idiopathic hypereosinophilic

syndrome.

Compounds of the invention may be useful as immunosuppressive agents and so have use in the treatment of auto-immune diseases such as allograft tissue rejection after transplantation, rheumatoid arthritis and diabetes.

Compounds of the invention may also be useful in inhibiting metastasis. Diseases of principal interest include asthma, COPD and inflammatory diseases of the upper respiratory tract involving seasonal and perennial rhinitis.

It will be appreciated by those skilled in the art that references herein to treatment or therapy extend to prophylaxis as well as the treatment of established conditions.

As mentioned above, compounds of formula (I) are useful as therapeutic agents.

There is thus provided as a further aspect of the invention a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

There is also therefore provided a compound of formula (I), or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.

According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof

for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.

In a further or alternative aspect there is provided a method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.

The compounds according to the invention may be formulated for administration in any convenient way.

There is thus further provided a pharmaceutical composition comprising a compound of formula (I), or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.

There is also provided a process for preparing such a pharmaceutical formulation which comprises admixing the compound of formula (I) or a physiologically acceptable salt or solvate thereof with one or more physiologically acceptable diluents or carriers.

The compounds according to the invention may, for example, be formulated for oral, inhaled, intranasal, buccal, parenteral or rectal administration, preferably for oral administration.

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, cellulose or polyvinyl pyrrolidone; fillers, for example, lactose, microcrystalline cellulose, sugar, maize- starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch, croscarmellose sodium or sodium starch glycollate; or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; or preservatives, for example, methyl or propyl *p*- hydroxybenzoates or sorbic acid. The preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

5 The compounds according to the invention may also be formulated for parenteral administration by bolus injection or continuous infusion and may be presented in unit dose form, for instance as ampoules, vials, small volume infusions or pre-filled syringes, or in multidose containers with an added preservative. The compositions may take such forms as solutions, suspensions,
10 or emulsions in aqueous or non-aqueous vehicles, and may contain formulatory agents such as anti-oxidants, buffers, antimicrobial agents and/or tonicity adjusting agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. The dry solid presentation may be prepared by filling a sterile powder aseptically
15 into individual sterile containers or by filling a sterile solution aseptically into each container and freeze-drying.

The pharmaceutical compositions according to the invention may also be used in combination with other therapeutic agents, for example anti-inflammatory agents such as corticosteroids, e.g. fluticasone propionate, beclomethasone
20 dipropionate, mometasone furoate, triamcinolone acetonide or budesonide; or non-steroidal anti-inflammatory drugs (NSAIDs) eg. sodium cromoglycate, nedocromil sodium, PDE-4 inhibitors, leukotriene antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists; or beta adrenergic agents such as salmeterol, salbutamol, formoterol,
25 fenoterol or terbutaline and salts thereof; or antiinfective agents e.g. antibiotic agents and antiviral agents. It will be appreciated that when the compounds of the present invention are administered in combination with other therapeutic agents normally administered by the inhaled or intranasal route, that the resultant pharmaceutical composition may be administered by the inhaled or intranasal
30 route.

Compounds of the invention may conveniently be administered in amounts of, for example, 0.001 to 500mg/kg body weight, preferably 0.01 to 500mg/kg body weight, more preferably 0.01 to 100mg/kg body weight, and at any appropriate frequency e.g. 1 to 4 times daily. The precise dosing regimen
35 will of course depend on factors such as the therapeutic indication, the age and condition of the patient, and the particular route of administration chosen.

Throughout the description and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated

integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.

The invention is illustrated by reference to, but is in no way limited by, the following Examples.

- 5 It should be noted that, for clarity, compounds of the Descriptions and the Examples are referred to by number, for example "Description 3" and "Example 5". The structures of the compounds so referred to are given in Table 1 for the Examples and Tables 2 and 3 for the Descriptions.

10 General experimental details

Mass Directed Automated Preparative HPLC column, conditions and eluent

- Mass directed automated preparative high performance liquid chromatography was carried out using an LCABZ+ 5 μ m (5cm x 10mm internal diameter) column, employing gradient elution using two solvent systems, (A) 0.1% formic acid in
15 water, and (B) 95% acetonitrile and 0.5% formic acid in water, at a flow rate of 8ml min⁻¹. Mass spectrometry was carried out using a VG Platform Mass Spectrometer, with an HP1100 Diode Array Detector and Accurate Flow Splitter.

LC/MS System

- The following Liquid Chromatography Mass Spectroscopy (LC/MS) System was
20 used:

- This system used an 3 μ m ABZ+PLUS (3.3cm x 4.6mm internal diameter) column, eluting with solvents: A – 0.1%v/v formic acid + 0.077% w/v ammonium acetate in water; and B – 95:5 acetonitrile:water + 0.05%v/v formic acid, at a flow rate of 3 ml per minute. The following gradient protocol was used: 100% A for
25 0.7mins; A+B mixtures, gradient profile 0 – 100% B over 3.5mins; hold at 100%B for 1.1mins; return to 100% A over 0.2mins.

The LC/MS system used a micromass spectrometer, with electrospray ionisation mode, positive and negative ion switching, mass range 80-1000 a.m.u.

Thermospray Mass Spectra

- 30 Thermospray Mass Spectra were determined on a HP 5989A engine mass spectrometer, +ve thermospray, source temperature 250°C, probe temperatures 120°C (stem), 190°C (tip), detection mass range 100-850 a.m.u. Compounds were injected in 10 μ l of a mixture of solvents comprising 65% methanol and 35% 0.05M aqueous ammonium acetate, at a flow rate of 0.7ml/min.

35 Solid phase extraction (ion exchange)

'SCX' refers to Isolute Flash SCX-2 sulphonic acid solid phase extraction cartridges.

Organic/Aqueous phase separation with hydrophobic frits

- 'Hydrophobic frit' refers to a Whatman polypropylene filter tube fitted with a PTFE
40 frit, pore size 5.0 μ m.

combined and the solvent evaporated in vacuo to give the title compound as a colourless oil (1.85g).

LC/MS (System A) R_t 1.77 min, Mass Spectrum m/z 275 [MH^+].

5 Description 4: [4-(3,4-Dichlorobenzyl)morpholin-2-yl]methylanine (alternative synthesis)

A mixture of 2-[(3,4-dichlorobenzyl)amino]ethanol (Chem Abs No. 40172-06-3, 0.980g) and 2-(oxiran-2-ylmethyl)-1H-isoindole-1,3(2H)-dione (1.10g) was heated at 80°C under nitrogen for 3h. The resulting solid mass was treated with concentrated sulphuric acid (1.5ml) then stirred at 150°C for 24h. The mixture was treated with water (100ml) then washed with ethyl acetate (2x100ml). The dark aqueous phase was basified to ~pH 12 using 5M aqueous sodium hydroxide, then extracted with ethyl acetate (2x100ml). The combined organic extracts were washed with water and brine, dried (Na_2SO_4) and concentrated under vacuum to give the title compound as a brown oil (1.02g).
Mass spec. m/z 275 (MH^+).

Description 5: 1-[(2S)-4-(3,4-Dichlorobenzyl)morpholin-2-yl]methylanine

Description 3 (racemic mixture, 8g) was separated into its single enantiomers by preparative chiral-HPLC. The separation was carried out using a 2" x 22cm Chiralpak AD 20µm column, Merck self pack DAC system, eluting with 95:5:0.1 (v/v) heptane : absolute ethanol: diethylamine (flow rate: 55ml/min over 40min, UV detection 225nm); sample load preparation: 400mg sample in 20ml 3:2 (v/v) absolute ethanol: system eluent.
25 The title compound (2.49g) was obtained as follows: preparative HPLC retention time 23.0 min.

Description 5 (Alternative procedure)

A slurry of Description 7 (1.00g) in water (8.5ml) was heated to 75° and then treated dropwise with concentrated sulphuric acid (2.5ml). The mixture was then heated at reflux. After 23h the reaction mixture was cooled to 22° and then treated with dichloromethane (6ml). 880 Ammonia solution (7ml) was then added dropwise with cooling. More dichloromethane (10ml) was added. The aqueous phase was separated and extracted with more dichloromethane (10ml).
35 The combined organic phase was washed with water (5ml) and then evaporated to dryness. The residue was redissolved in dichloromethane and the solvent re-evaporated to give the product as an oil (662mg).

Description 6: 1-[(2S)-4-(3,4-Dichlorobenzyl)morpholin-2-yl]methanamine salt
40 with D-tartaric acid 1:1

Description 3 (0.613g) was dissolved in methanol (12.3ml). D-Tartaric acid (0.335g) was added and the slurry was heated to reflux for 50min. The mixture was allowed to cool to 0-5°C and the precipitate isolated by filtration to give the title compound as a white solid (0.4g).

5 ee: 76%ee

Chiral analytical HPLC (Chiralpak AD column, 4.6 x 250mm, eluent 50:50:0.1 MeOH: EtOH: Butylamine, flow rate 0.5ml/min, UV detection at 220nm), Rt 8.9min.

10 Description 7: 2-[4-(3,4-Dichloro-benzyl)-morpholin-2-ylmethyl]-isoindole-1,3-dione

A mixture of 2-[(3,4-dichlorobenzyl)amino]ethanol (2.038 g) and (S)-2-(oxiran-2-ylmethyl)-1H-isoindole-1,3(2H)-dione (2.032g) in tetrahydrofuran (3.3ml) was stirred and heated at reflux under nitrogen. After 21.5h more tetrahydrofuran

- 15 (12.5ml) was added and the mixture was cooled to 3°. Triphenyl phosphine (2.793g) was added and the mixture was stirred until all the solid had dissolved. Diisopropylazodicarboxylate (2.1ml) was then added over 12min maintaining the temperature at <7°. After 2.25h the mixture was allowed to warm to 22°. After 5.3h more triphenylphosphine (121mg) and diisopropylazodicarboxylate (0.09ml)
- 20 were added. After 22.5h the reaction mixture was concentrated to near dryness. Propan-2-ol (12ml) was added and the concentration repeated, this was repeated once more. More propan-2-ol (12ml) was added and the mixture was heated to 70°. After 0.5h the slurry was cooled to 22° and then after a further 2h the product was collected. The bed was washed with propan-2-ol (2x4ml) and
- 25 then dried in vacuo at 40° to give the product, (2.622g).


Description 8: [(2S)-4-(3,4-difluorobenzyl)morpholin-2-yl]methanamine

Description 8 was made in an analogous manner to that of Description 5.

Preparative HPLC retention time 28.3min

30

Description 9:




- A solution of Description 5 (1.45g) in dichloromethane (25ml) was treated with bromoacetic acid (3.65g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10.1g) and the mixture stirred at room temperature for 3 hours. The solution was then washed with aqueous sodium hydrogen carbonate, and the aqueous phase extracted with dichloromethane. The combined organic phases were dried (Na_2SO_4) and concentrated in vacuo to give a brown oil. Purification by chromatography on silica gel, eluting with 5% ethanol / dichloromethane, gave the title compound (1.167g) as a yellow oil.
- LC-MS : Rt = 2.30min. Mass Spectrum m/z 397 [MH^+]


Description 10

Description 10 was prepared in an analogous manner to that of Description 12.

15




Description 11




20

- Potassium tert butoxide (0.045g) was added, in portions, to a stirred solution of 3-(ethoxycarbonyl)pyrazole [CAS 37622-90-5] (0.050g) in N,N-dimethylformamide (0.5ml). The mixture was stirred for 5 min then tert-butylbromoacetate (0.078g) was added, in portions over 2 min. The mixture was stirred for 0.75h then partitioned between ethyl acetate (30ml) and 1.0M aqueous sodium bicarbonate (20ml). The organic phase was separated, washed with water (2x20ml), dried (Na_2SO_4) and concentrated in vacuo to give the title compound (0.073g) as a colourless, viscous oil.
- LC-MS (System A): Rt = 2.78min. Mass Spectrum m/z 255 [MH^+]

Description 12 (starting material for Example 18)

- 5 A solution of 4.0M hydrogen chloride in dioxan (0.5ml) was added to a stirred solution of Description 11 (0.070g) in 1,4-dioxan (3ml). The mixture was stirred for 4h. More 4.0M hydrogen chloride in dioxan (0.5ml) was added. The mixture was stirred for a further 3h then left to stand over the weekend. The solvent and excess hydrogen chloride were removed in vacuo to give the title compound
- 10 (0.056g) as a pale yellow, waxy solid.

LC-MS (System A): Rt = 1.98min. Mass Spectrum m/z 199[MH⁺] and 197 [MH⁺]

Examples15 Synthetic Method AExample 10

- 20 A solution of 1H-tetrazole-5-acetic acid (0.172g) in N,N-dimethylformamide (2ml) was treated with 1-hydroxybenzotriazole (0.124g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.200g), Description 5 (0.176g) as a solution in N,N-dimethylformamide (1ml) and N,N-diisopropylethylamine (0.112ml), and the mixture stirred at room temperature for six days. The solution was then diluted
- 25 with dichloromethane (30ml) and washed successively with saturated aqueous sodium hydrogen carbonate (30ml) and dilute aqueous sodium chloride (2 x 30ml). The organic phase was separated using three hydrophobic frits (12ml) and drained directly onto an SCX (10g) ion exchange cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10%
- 30 0.880 ammonia/methanol. The basic fractions were combined and evaporated to give a brown film which was redissolved in dichloromethane and purified by

A solution of 5-isopropyltetrazole (Tetrahedron (1999), 55(29), 8997-9006) (0.095g) in N,N-dimethylformamide (10ml) was treated with lithium bis(trimethylsilyl)amide (0.155g) and stirred at room temperature for twenty five minutes. Description 9 (0.167g) was then added as a solution in N,N-dimethylformamide (10ml) and the mixture stirred at 60° for 16 hours. After cooling, the solvent was removed, the residue was dissolved in dichloromethane and this solution washed with water. The aqueous phase was extracted with dichloromethane, then the combined organic phases were dried (Na₂SO₄), and the solvent concentrated under vacuum to give a residue which was purified using mass directed HPLC. Appropriate fractions were combined and evaporated to give the title compound Example 6 (0.021g) as a colourless oil.


LC-MS : Rt = 2.21min. Mass Spectrum m/z [MH⁺] 427

Appropriate other fractions were combined and evaporated to give the title compound Example 3 (0.027g) as a colourless oil.

LC-MS : Rt = 2.35min. Mass Spectrum m/z [MH⁺] 427

Synthetic Method C (interconversion)

Example 4 and Example 9



A stirred solution of Example 10 (0.038g) in dichloromethane (1.5ml) and methanol (0.5ml) was treated dropwise at room temperature with (trimethylsilyl)diazomethane (0.22ml of 10% solution in hexane). After 2 hours stirring at room temperature, acetic acid (0.1ml) was added and the solvent evaporated under a stream of nitrogen to dryness. The residue was loaded onto an SCX (2g) ion exchange cartridge, which had been pre-treated with methanol and which was then eluted with methanol and 10% 0.880 ammonia/methanol. The basic fractions were combined and evaporated and the residue was purified

by chromatography on silica gel (Varian Bond Elut, 2g), eluting with 5% methanol/ethyl acetate then methanol. Mixed fractions were repurified similarly on silica gel (Varian Bond-Elut, 1g) to give the title compound Example 4 (0.0073g) as a clear colourless film.

5

LC-MS : Rt = 2.14 min. Mass Spectrum m/z 399 [MH⁺]


Other appropriate fractions were combined and evaporated to give the title compound Example 9 (0.0061g) as a clear colourless film.

10








LC-MS : Rt = 2.14 min. Mass Spectrum m/z 399 [MH⁺]

15

Table 1



Ex. No.	Synthetic Method	R ¹	R ²	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] ⁺ of lowest mass isomer unless otherwise indicated
1	B		3,4-di-ClPh	S	466.393	466
2	B		3,4-di-ClPh	S	468.39	468
3	B		3,4-di-ClPh	S	427.337	427
4	A+C		3,4-di-ClPh	S	399.283	399
5	B		3,4-di-FPh	S	446.523	447

Ex. No.	Synthetic Method	R ¹	R ²	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] ⁺ of lowest mass isomer unless otherwise indicated
6	B		3,4-di-ClPh	S	427.337	427
7	B		3,4-di-ClPh	S	465.306	465
8	B		3,4-di-ClPh	S	468.39	468
9	A+C		3,4-di-ClPh	S	399.283	399
10	A		3,4-di-ClPh	S	385.256	385
11	A		3,4-di-FPh	S	365.383	366
12	A		3,4-di-ClPh	S	398.292	398








Ex. No.	Synthetic Method	R ¹	R ²	Stereochem at position (*)	Calculated Mol. Wt.	Observed Mol. Wt. (LC/MS) [M+H] ⁺ of lowest mass isomer unless otherwise indicated
13	A		3,4-di-FPh	S	365.383	366
14	A		3,4-di-ClPh	S	398.292	398
15	A		3,4-di-ClPh	S	411.291	411
16	A		3,4-di-ClPh	S	397.308	397
17	A		3,4-di-ClPh	S	411.335	411
18	A		3,4-di-ClPh	S	455.345	455

Table 2



Description No.	R ¹	R ²	Stereochem at position (*)
1	BrCH ₂ CO-	3,4-di-ClPh	S
9	BrCH ₂ CO-	3,4-di-ClPh	S

5


Table 3

Description No.	Structure
10	
11	
12	

10

Claims

1. A compound of formula (I):



5

wherein:

- R^1 represents substituted or unsubstituted heteroaryl;
 Y represents $-(\text{CR}_{\text{na}}\text{R}_{\text{nb}})_n-$;
 R_{na} and R_{nb} are each independently hydrogen or C_{1-6} alkyl;
 n is an integer from 1 to 5;
 R^2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;
 R^3 represents hydrogen or C_{1-6} alkyl;
- 15 and salts and solvates thereof;
 with the provisos that;
 R^1 is not oxazolyl;
 R^1 is not substituted by phenyl, and;
 the following compounds are excluded;
- 20 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide;
 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-thien-3-ylacetamide;
 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)acetamide;
- 25 2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide;
 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-furyl)acetamide;
- 30 2-(3-acetyl-1-benzothien-4-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide trifluoroacetate;
 2-(5-bromopyridin-3-yl)-N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]acetamide compound with formic acid (1:1);
 N-[[4-(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(2-furyl)acetamide;

- 2-(4-bromo-1H-imidazol-1-yl)-N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)acetamide;
 N-([4-(3,4-difluorobenzyl)morpholin-2-yl]methyl)-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 5 N-([4-(4-fluorobenzyl)morpholin-2-yl]methyl)-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 N-([4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl)-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 N-([4-((5-chlorothien-2-yl)methyl)morpholin-2-yl]methyl)-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 10 N-([4-(3-chlorobenzyl)morpholin-2-yl]methyl)-2-(2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-methyl-2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide;
 15 methyl 2-[2-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)amino]-2-oxoethyl]-2H-1,2,3-benzotriazole-5-carboxylate;
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(1H-pyrrolo[2,3-b]pyridin-1-yl)acetamide;
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-pyridin-2-yl-2H-tetraazol-2-yl)acetamide;
 20 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-pyridin-3-yl-2H-tetraazol-2-yl)acetamide;
 methyl 1-[2-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)amino]-2-oxoethyl]-1H-1,2,3-benzotriazole-5-carboxylate compound with methyl 1-[2-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)amino]-2-oxoethyl]-1H-1,2,3-benzotriazole-6-carboxylate (1:1);
 25 N-([(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(5-methyl-2-pyrazin-2-yl-1,3-thiazol-4-yl)acetamide, and;
 N-([4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl)-2-(2,3-dimethylquinoxalin-6-yl)acetamide.
 30

2. A compound of formula (I) according to claim 1 and salts and solvates thereof wherein R¹ is unsubstituted or substituted isoxazolyl, unsubstituted or substituted pyrazolyl or substituted or unsubstituted tetrazolyl.


35

3. A compound of formula (I) according to claim 1 or claim 2 and salts and solvates thereof wherein R¹ is 3-(thiophen-2-yl)-4-(methyl)pyrazol-1-yl, 5-(*iso*-propyl)tetrazol-1-yl, 5-methyl-3-(trifluoromethyl)pyrazol-1-yl, 3-(thiazol-2-yl)pyrazol-1-yl, 5-(piperidin-1-yl)tetrazol-2-yl, 5-(piperidin-1-yl)tetrazol-1-yl, 1-(methyl)tetrazol-5-yl, tetrazol-5-yl, 5-(methyl)isoxazol-3-yl, 5-(*iso*-propyl)tetrazol-

40

2-yl, 2-(methyl)tetrazol-5-yl, 3-(methyl)isoxazol-5-yl, 3-(formyl)pyrazol-1-yl, 3-(methyl)pyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, or 4-(ethoxycarbonyl)pyrazol-1-yl.

4. A compound of formula (I) according to any one of claims 1 to 3 and salts
5 and solvates thereof wherein R_{na} and R_{nb} are both hydrogen.
5. A compound of formula (I) according to any one of claims 1 to 4 and salts
and solvates thereof wherein n is 1.
- 10 6. A compound of formula (I) according to any one of claims 1 to 5 and salts
and solvates thereof wherein R^3 is hydrogen.
7. A compound of formula (I) according to any one of claims 1 to 6 and salts
and solvates thereof wherein R^2 is unsubstituted or substituted phenyl or
15 unsubstituted or substituted thiophenyl.
8. A compound of formula (I) according to any one of claims 1 to 7 and salts
and solvates thereof wherein R^2 is phenyl substituted with chloro or fluoro.
- 20 9. A compound of formula (I) according to any one of claims 1 to 8 and salts
and solvates thereof wherein R^2 is 3,4-difluorophenyl or 3,4-dichlorophenyl.
10. A compound of formula (I') according to claim 1



25

wherein;

R^1 is unsubstituted or substituted heteroaryl, and;


R^2 is phenyl substituted with halo;

30 and salts and solvates thereof.

11. A compound of formula (I') according to claim 10 and salts and solvates
thereof wherein, R^1 is pyrazolyl substituted with thiophenyl, thiazolyl, formyl, C_{1-6}
alkoxycarbonyl, C_{1-6} alkyl, or perhalo C_{1-6} alkyl; unsubstituted tetrazolyl or

tetrazolyl substituted with piperidiny1 or C₁₋₆alkyl; or isoxazolyl substituted with C₁₋₆alkyl.

12. A compound of formula (I') according to claim 10 or claim 11 and salts
 5 and solvates thereof wherein R¹ is 3-(thiazol-2-yl)pyrazol-1-yl, 5-(1-piperidinyl)tetrazol-2-yl, 5-(*iso*-propyl)tetrazol-2-yl, 2-methyltetrazol-5-yl, 4-methyl-3-(thiophen-2-yl)pyrazol-1-yl, 5-(*iso*-propyl)tetrazol-1-yl, 5-methyl-3-(trifluoromethyl)pyrazol-1-yl, 5-(piperidin-1-yl)tetrazol-1-yl, 1-methyltetrazol-5-yl, tetrazol-5-yl, 3-(methyl)isoxazol-5-yl, 3-(formyl)pyrazol-1-yl, 3-(methyl)pyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 4-(ethoxycarbonyl)pyrazol-1-yl, or 5-methylisoxazol-3-yl.
13. A compound of formula (I') according to any one of claims 10 to 12 and salts and solvates thereof wherein R² is phenyl substituted with chloro or fluoro.
14. A compound of formula (I') according to any one of claims 10 to 13 and salts and solvates thereof wherein R² is 3,4-dichlorophenyl or 3,4-difluorophenyl.
15. A process for the preparation of a compound of formula (I) which process
 20 comprises the reaction of a compound of formula (II) with a compound of formula (III);




25 wherein;

R¹, Y, R³, and R² are as hereinbefore defined for formula (I) in the presence of an activating agent and a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
 30 (ii) removing any necessary protecting group;
 (iii) preparing a salt or solvate of the compound so formed.


16. A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

17. A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.
18. Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.
19. A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
20. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.
21. A compound of formula (IIIBR)




wherein A is a protected amino group and R² is as defined for formula (I) in claim 1.

22. There is also provided a compound of formula (IIIBE).



wherein A is a protected amino group and R² is as defined for formula (I) in claim 1.


23. There is also provided a compound of formula (XIII).



5 wherein L^2 is a leaving group and R^3 and R^4 are as defined for formula (I) in claim 1.

Abstract

Compounds of formula (I):



5

wherein:

R¹ represents substituted or unsubstituted heteroaryl;

Y represents -(CR_{na}R_{nb})_n-;

10 R_{na} and R_{nb} are each independently hydrogen or C₁₋₆alkyl;

n is an integer from 1 to 5;

R² represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R³ represents hydrogen or C₁₋₆alkyl;

15 and salts and solvates thereof are CCR-3 antagonists and are thus indicated to be useful in therapy.